Description of Research Expertise
I am a physician scientist working to characterize novel pathways in kidney podocyte injury and survival. Our goal is to advance the understanding of the underlying mechanism of glomerular disease progression while identifying potential targets for therapeutic intervention. We have identified the novel pro-injury signaling molecule dendrin as a key mediator of podocyte injury. We found that dendrin ablation delayed the onset and severity of proteinuria, renal failure, podocyte loss and most importantly, improved survival in a rodent model of progressive focal segmental glomerulosclerosis (FSGS). Additionally, we found that the Hippo signaling pathway Yes-Associated Protein (YAP) is an inhibitor of dendrin pro-injury function. We recently demonstrated that podocyte-specific deletion of YAP results in an FSGS phenotype analogous to human disease. These findings are significant as they establish dendrin as a potential therapeutic target in treating proteinuric disease and open the door to further definition of the role of the Hippo signaling pathway in podocyte hemeostasis. Our current research focus centers on determining the role of dendrin in glomerular cell crosstalk and disease progression while developing a pharmacologic strategy for dendrin inhibition. In parallel our group will continue to define the role of the Hippo pathway in podocytes under normal and disease conditions in an effort consistent with our goals of enhancing the therapeutic pipeline in this clinical area where no cell-specific therapy is currently clinically available.
Selected Publications
Meliambro K, He JC, Campbell KN.: Podocyte-targeted therapies - progress and future directions Nat Rev Nephrol 20 (10): 643-658,2024.
Cantarelli C, Campbell KN, Cravedi P.: Parietal epithelial cells in glomerulosclerosis: a new piece in the puzzle? J Nephrol : 2024.
de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, Morgan P, Meliambro K, Egerman M, Ray J, Parker T, Levine D, Seshan S, Bardash Y, Horowitz B, Kent CA, Shaw MM, Perlman A, Moledina DG, Coca SG, Campbell KN.: Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease Am J Kidney Dis 84 (2): 205-214.e1,2024.
Li J, Wisnivesky JP, Lin JJ, Campbell KN, Hu L, Kale MS.: Examining the Trajectory of Health-Related Quality of Life among Coronavirus Disease Patients J Gen Intern Med 39 (10): 1820-1827,2024.
Suresh V, Stillman IE, Campbell KN, Meliambro K.: Focal Segmental Glomerulosclerosis Adv Kidney Dis Health 31 (4): 275-289,2024.
Jhaveri KD, Campbell KN, Gibson KL.: Nephrotic Syndrome: Have We Entered a New Era? Adv Kidney Dis Health 31 (4): 265-266,2024.
Campbell KN, Gibson KL, Jhaveri KD.: Nephritic Syndromes: A Lot to Progress Adv Kidney Dis Health 31 (3): 167-169,2024.
Campbell KN, Gesualdo L, Murphy E, Rheault MN, Srivastava T, Tesar V, Komers R, Trachtman H.: Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety Kidney Med 6 (6): 100833,2024.
Campbell KN, Griffin S, Trachtman H, Geletka R, Wong MG.: Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice Int J Nephrol Renovasc Dis 16 : 281-291,2023.
Shilane D, Miller S, Fleming J, Bar J, Corbin Y, Garcia M, Gasner MR, Campbell KN, Brown S, Weber E.: Barriers to Telehealth Utilization Among Patients of Limited Income with Chronic Conditions and a Gap in Care Telemed J E Health 29 (11): 1659-1666,2023.
Academic Contact Information
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1243
New York,
NY
10029
Patient appointments: 800-789-7366